ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript
Source: SeekingAlpha
2025-12-07 01:38:52 ET
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer December 6, 2025 8:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript
Oric Pharmaceuticals Inc.
NASDAQ: ORIC
ORIC Trading
-1.16% G/L:
$11.623 Last:
353,868 Volume:
$11.96 Open:
ORIC Latest News
ORIC Stock Data
$1,023,561,322
83,384,701
0.22%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
